Ixekizumab (Taltz®) is a new treatment option for Australians with ankylosing spondylitis – a chronic form of arthritis that affects the spine and pelvis.
Rheumatoid arthritis pain isn’t easy to manage when providers can’t see and touch your joints in person, but you can discuss and treat RA pain during telehealth visits. Here’s how.
CreakyJoints Australia launched the inaugural edition of A Patient’s Guide to Living with Axial Spondyloarthritis in Australia as a free download from their website today to coincide with World Arthritis Day.
Without opioids, my life is sedentary. By taking my opioids away, my pain management doctor is increasing my risk of obesity, heart disease and disability. Not to mention severe, daily pain.
It can be a big adjustment to give yourself injections. These tips can make the process less scary.
What should you do if you can’t access Plaquenil? Are you at risk of COVID-19 exposure if you have a biologic infusion in a hospital? We’ve got the answers you’ve been seeking.
Do you regularly attend face-to-face health appointments such as medication reviews, physiotherapy and blood tests? Should you still go during the lockdown?
The question on everyone’s lips is when will we have a cure for COVID-19?
The new OA guidelines are designed more like a menu from which patients and providers can choose one or more approved items.
It’s not surprising that you can feel arthritis in your feet: The disease predominantly affects your joints, and your foot contains more than 30 of them.
Tofacitinib (Xeljanx®) is now available on the Pharmaceutical Benefits Scheme (PBS) for those diagnosed with psoriatic arthritis.
On 1 March, 2019, ixekizumab (Taltz®), was added to the Pharmaceutical Benefits Scheme (PBS) to give adults with severe psoriatic arthritis more treatment options. Previously, Australian adults had been able to access the medication, but at a cost of around...
This steroid is commonly prescribed to help with RA flares. Here’s what you need to know before you start it.
A new study compared infection risks among different biologics for RA — and Orencia came out ahead.